Literature DB >> 35475071

Mechanical Valve Thrombosis Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report.

Carolina Cardona Buitrago1, Aida Maired Builes Gutierrez2, David Jiménez Marín3, Camilo Aristizábal García1.   

Abstract

Although the association of coronavirus disease 2019 (COVID-19) and thromboembolic disease is well known, cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and mechanical valve thrombosis have not been described enough. Mechanical valve thrombosis is a medical emergency that is associated with a great impact on patients' morbidity and mortality. Here, we report a case of a patient with mechanical valve thrombosis secondary to SARS-CoV-2 infections that required valve replacement with satisfactory postoperative recovery. A 52-year old female patient was presented with a previously implanted mechanical prosthesis (type - St. Jude Medical 29 mm; St. Paul, MN: St. Jude Medical, Inc.) eight years ago due to rheumatic fever, under anticoagulation with warfarin and valvular atrial fibrillation (permanent), congenital single kidney (glomerular filtration rate {GFR}: 89.9 mL/min), and hypothyroidism. She was admitted to the hospital with a high level of complexity due to respiratory difficulty and generalized edematous syndrome, and a reverse transcription-polymerase chain reaction (RT-PCR) confirmed COVID-19 infection (20 days before admission); the patient was anticoagulated with warfarin (international normalized ratio {INR} at admission was 2.63 seconds). As per protocol, a CT-chest scan tomography was performed and showed organized pneumonia in the right apical lobe. We performed a transesophageal echocardiogram, which showed a thrombus (20 x 15 x 20 mm) in the lateral disc of the mechanical prosthesis, restricting its mobility. The patient presented signs of hypoperfusion (lactate levels: 4 mmol/L; urine per hour: 1 cc/kg) with associated low cardiac output syndrome, requiring double vasopressor support at the maximum dose (achieving a mean arterial pressure of 72 mmHg) due to the clinical condition and the large size of the thrombus, the cardiovascular surgeon, in agreement with the family, decides to carry out emergency valve replacement surgery with replacement of a mechanical prosthesis replacement (St. Jude No. 29; St. Paul, MN: St. Jude Medical, Inc.). The patient presented a satisfactory postoperative recovery, achieving INR goals, with subsequent discharge and follow-up at two months with transthoracic ultrasound, where normofunctional mitral prosthesis was demonstrated, without evidence of thrombi or intracavitary masses. Mechanical mitral valve thrombosis, secondary to SARS-CoV-2 infection is a serious complication with poor prognosis that requires a high rate of suspicion, and timely diagnostic aids are essential to confirm the diagnosis. Managing this issue should be interdisciplinary and individualized considering the clinical condition of the patient and the associated comorbidities.
Copyright © 2022, Cardona Buitrago et al.

Entities:  

Keywords:  coronavirus infections; covid-19; mitral valve; sars-cov-2; thrombosis

Year:  2022        PMID: 35475071      PMCID: PMC9018927          DOI: 10.7759/cureus.23358

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  14 in total

1.  Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System.

Authors:  Seda Bilaloglu; Yin Aphinyanaphongs; Simon Jones; Eduardo Iturrate; Judith Hochman; Jeffrey S Berger
Journal:  JAMA       Date:  2020-08-25       Impact factor: 56.272

2.  Thromboinflammation and the hypercoagulability of COVID-19.

Authors:  Jean M Connors; Jerrold H Levy
Journal:  J Thromb Haemost       Date:  2020-05-26       Impact factor: 5.824

3.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Authors:  Catherine M Otto; Rick A Nishimura; Robert O Bonow; Blase A Carabello; John P Erwin; Federico Gentile; Hani Jneid; Eric V Krieger; Michael Mack; Christopher McLeod; Patrick T O'Gara; Vera H Rigolin; Thoralf M Sundt; Annemarie Thompson; Christopher Toly
Journal:  J Am Coll Cardiol       Date:  2020-12-17       Impact factor: 24.094

4.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.

Authors:  Songping Cui; Shuo Chen; Xiunan Li; Shi Liu; Feng Wang
Journal:  J Thromb Haemost       Date:  2020-05-06       Impact factor: 5.824

5.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.

Authors:  Julie Helms; Charles Tacquard; François Severac; Ian Leonard-Lorant; Mickaël Ohana; Xavier Delabranche; Hamid Merdji; Raphaël Clere-Jehl; Malika Schenck; Florence Fagot Gandet; Samira Fafi-Kremer; Vincent Castelain; Francis Schneider; Lélia Grunebaum; Eduardo Anglés-Cano; Laurent Sattler; Paul-Michel Mertes; Ferhat Meziani
Journal:  Intensive Care Med       Date:  2020-05-04       Impact factor: 17.440

6.  Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19.

Authors:  Guillem Llopis Gisbert; Verónica Vidal Urrutia; Miguel A Moruno Benita; Ana Payá Chaume; Alberto Berenguer Jofresa; Andrés M Cubillos Arango; José L Pérez Boscá; Rafael Payá Serrano
Journal:  Can J Cardiol       Date:  2020-10-24       Impact factor: 5.223

7.  Thrombolysis for COVID-19-associated bioprosthetic mitral valve thrombosis with shock.

Authors:  Shravya Vinnakota; Jacob C Jentzer; Sushil A Luis
Journal:  Eur Heart J       Date:  2021-06-11       Impact factor: 29.983

8.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-10       Impact factor: 3.944

9.  COVID-19 and its implications for thrombosis and anticoagulation.

Authors:  Jean M Connors; Jerrold H Levy
Journal:  Blood       Date:  2020-06-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.